| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
INFLAMMATORY BOWEL DISEASE |
1 University Division of Medicine, Bristol Royal Infirmary, Bristol, UK,
2 First Medical Department, Christian-Albrechts-University, Kiel, Germany
3 Western General Hospital, Edinburgh, UK
4 St Mark’s Hospital, Harrow, London, UK
Correspondence to:
Correspondence to:
Dr C S J Probert, University Division of Medicine, Bristol Royal Infirmary, Marlborough St, Bristol BS2 8HW, UK;
c.s.j.probert{at}bristol.ac.uk
Background: Tumour necrosis factor production is increased in the mucosa of patients with active ulcerative colitis. The benefits of infliximab in Crohn’s disease are established. We investigated its efficacy in ulcerative colitis.
Methods: We conducted a randomised placebo controlled trial of infliximab (5 mg/kg) in the treatment of glucocorticoid resistant ulcerative colitis. Infusions were given at weeks 0 and 2. Disease activity and quality of life were recorded over eight weeks of follow up. Remission was defined as an ulcerative colitis symptom score (UCSS) of 
2 and/or Baron score of 0 at week 6. Patients not in remission were offered open label infliximab 10 mg/kg and reviewed two weeks later.
Results: After two weeks, there was no statistically significant difference between the infliximab and placebo groups in the proportion of patients with a Baron score of 0 (13% (3/23) v 5% (1/19) (95% confidence interval (CI) -9% to 24%); p=0.74). After six weeks, remission (UCSS 2) rates were 39% (9/23) versus 30% (6/20) (95% CI -19 to 34%; p=0.76). The median improvement in UCSS was 3 for the infliximab group and 2.5 for the placebo group (p=0.82, Mann-Whitney U test). A Baron score of 0 was likely in either group (26% (6/23) v 30% (6/20) (95% CI -30% to 23%); p=0.96). Improvement in the IBDQ and EuroQol was not significantly different between the groups (p=0.22 and 0.3, respectively, Mann-Whitney U test). Twenty eligible patients were given open labelled infusions. Remission was achieved in 3/11 (27%) patients initially treated with infliximab and in 1/9 (11%) patients treated with placebo.
Conclusion: These data do not support the use of infliximab in the management of moderately active glucocorticoid resistant ulcerative colitis.
Keywords: ulcerative colitis; infliximab; clinical trial; inflammatory bowel disease; glucocorticoids; steroids
Abbreviations: TNF, tumour necrosis factor 
; UCSS, ulcerative colitis symptom score; QOL, quality of life; IBDQ, QOL index for inflammatory bowel disease; MW, Mann-Whitney U test; CRP, C reactive protein
This article has been cited by other articles:
|
|
 |
|
  B. E. Sands and G. G. Kaplan The Role of TNF{alpha} in Ulcerative Colitis J. Clin. Pharmacol., August 1, 2007; 47(8): 930 - 941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K R Herrlinger, K Fellermann, and E F Stange Tacrolimus--finally! Gut, September 1, 2006; 55(9): 1224 - 1225. [Full Text] [PDF]
|
|
|
|
|
|
H Ogata, T Matsui, M Nakamura, M Iida, M Takazoe, Y Suzuki, and T Hibi A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis Gut, September 1, 2006; 55(9): 1255 - 1262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Ardizzone, G Maconi, A Russo, V Imbesi, E Colombo, and G Bianchi Porro Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis Gut, January 1, 2006; 55(1): 47 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Rutgeerts, W. J. Sandborn, B. G. Feagan, W. Reinisch, A. Olson, J. Johanns, S. Travers, D. Rachmilewitz, S. B. Hanauer, G. R. Lichtenstein, et al. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis N. Engl. J. Med., December 8, 2005; 353(23): 2462 - 2476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W J Sandborn and W A Faubion Biologics in inflammatory bowel disease: how much progress have we made? Gut, September 1, 2004; 53(9): 1366 - 1373. [Full Text] [PDF]
|
|
|
|
|
|
W J Sandborn and E V Loftus Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease Gut, June 1, 2004; 53(6): 780 - 782. [Full Text]
|
|
|
|
|
|
T Ljung, P Karlen, D Schmidt, P M Hellstrom, A Lapidus, I Janczewska, U Sjoqvist, and R Lofberg Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County Gut, June 1, 2004; 53(6): 849 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Infliximab Fails to Show Benefit for Moderately Severe, Steroid-Resistant Ulcerative Colitis Journal Watch Gastroenterology, August 26, 2003; 2003(826): 2 - 2. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
